Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 4Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 4Genitourinary 4CNS 4Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 3Dermatologic 3Head & Neck 2Breast 2Thoracic 1Other neoplasm 1Myeloid 1Gynecologic 1

Conditions

Breast Neoplasms 2Neoplasm Metastasis 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 100Trastuzumab 81pembrolizumab 76Fulvestrant 68Cyclophosphamide 66Carboplatin 47Capecitabine 47Docetaxel 45palbociclib 41Lapatinib 40Letrozole 37Doxorubicin 29olaparib 28Taxes 28Nivolumab 25Magnetic Resonance Spectroscopy 25Gemcitabine 25130-nm albumin-bound paclitaxel 25Everolimus 23Biopsy 23ribociclib 22abemaciclib 21Specimen Handling 21Albumin-Bound Paclitaxel 21Radiotherapy 19Cisplatin 19Bevacizumab 19Ado-Trastuzumab Emtansine 19pertuzumab 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Gene Expression Profiling × Breast × Clear all
NCT00379509 2017-03-21

Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer

UNC Lineberger Comprehensive Cancer Center

Phase 1 Completed
20 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00544804 2014-07-02

Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2

University of California, San Francisco

Phase 1 Completed
41 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡